Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Structure Therapeutics

2 ‘Monster’ Stocks to Snap Up Before 2025

Analysts at Jefferies have identified Metagenomi and Structure Therapeutics as two "monster" stocks in the biotech sector, with potential gains of up to 1,000%.

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

Investors Business Daily

This Weight-Loss Stock Just Scored a New Street-High Price Target

This Weight-Loss Stock Just Scored a New Street-High Price Target

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Investors Business Daily

Structure Therapeutics vs. Viking Therapeutics: Which Weight-Loss Drug Stock Wins?

With weight-loss drugs gaining traction, which biopharma stock wins?

Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results

Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug.

Investors Business Daily

JPMorgan Forecast Over 85% Upside for Two Biopharma Stocks Targeting Obesity and Chronic Conditions

The two biopharma firms have developed drug candidates to treat autoimmune and pulmonary diseases. They have demonstrated good safety profiles and efficacy in various stages of clinical trials.

International Business Times UK

inkl

Read news from The Economist, FT, and more,
with one subscription

This Weight-Loss Stock Could Surge 75%, Says JPMorgan

This Weight-Loss Stock Could Surge 75%, Says JPMorgan

Structure Therapeutics is a clinical-stage weight-loss company that is poised to gain traction in a rapidly expanding addressable market.

Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Biotech stocks are heating up as multibillion-dollar deals pile up and new modalities like CRISPR gene-editing hit prime time.

Investors Business Daily

People

119,877 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Viking Therapeutics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

277,136 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play